Kinnate to Sell Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Lab

 

• Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.

• The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives.

• This acquisition is intended to enable Pierre Fabre Laboratories to pursue its efforts in the field of precision oncology and provide it the opportunity to broaden its reach to patients in need for targeted therapies in RAF and RAS solid tumors.  

https://finance.yahoo.com/news/kinnate-biopharma-inc-sells-investigational-133500289.html

GoodRx upped to Overweight from Neutral by JPMorgan

 Target to $10 from $7

https://finviz.com/quote.ashx?t=GDRX&ty=c&ta=1&p=d

Shattuck results & highlights

- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontline TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients; initial data build on the dose-escalation data featured in a poster presentation at the American Society of Hematology (ASH) Annual Meeting –

- Completed initial enrollment in Phase 1B dose-expansion cohorts for frontline HR-MDS and TP53m AML patients in the fourth quarter of 2023; additional enrollment ongoing, with updated combination data expected mid-year 2024 –

- Completed enrollment and presented positive interim data from the Phase 1B clinical trial of SL-172154 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC), which demonstrated an acceptable safety profile and encouraging anti-tumor activity that compares favorably to PLD as a monotherapy –

- Entered into strategic collaboration and license agreement with Ono Pharmaceutical Co., Ltd (Ono) to generate novel bifunctional fusion proteins with the potential to treat autoimmune and inflammatory diseases –

- Completed $50 million offering of common stock and pre-funded warrants in the fourth quarter of 2023, extending cash runway into 2026 –

https://www.globenewswire.com/news-release/2024/02/29/2838402/0/en/Shattuck-Labs-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights.html

Cardiff Oncology Results

 

• Cash Position: $75 million in cash and equivalents as of December 31, 2023, with a projected runway into Q3 2025.

• Operating Expenses: Increased to $45.9 million for the full year 2023, up from $40.3 million in 2022.

• Net Loss: Reported a net loss of $41.4 million for the full year 2023, compared to a net loss of $38.7 million in 2022.

• Research and Development: R&D expenses rose to $32.9 million, reflecting investment in clinical programs and development of lead drug candidate, onvansertib.

• Revenue: Royalty revenues increased slightly to $488,000 in 2023 from $386,000 in 2022.

On February 29, 2024, Cardiff Oncology Inc (NASDAQ:CRDF) released its 8-K filing, detailing the financial results for the fourth quarter and the full year ended December 31, 2023, and providing a business update. The clinical-stage biotechnology company, known for developing treatment options for cancer patients, particularly in indications with significant medical needs, has reported several key milestones and financial metrics that are critical for investors to understand.

Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results

Financial Performance and Strategic Highlights

Cardiff Oncology's financial results reflect a company in the midst of advancing its clinical programs, with a focus on its lead drug candidate, onvansertib. The company reported a net loss of $41.4 million for the full year 2023, which is an increase from the net loss of $38.7 million reported in the previous year. This loss is attributed to the increased operating expenses, which rose to $45.9 million for the year, up from $40.3 million in 2022. The increase in expenses was primarily due to the costs associated with clinical programs and the development of onvansertib.

Despite the increased net loss, Cardiff Oncology's cash position remains strong, with cash and equivalents totaling $75 million as of December 31, 2023. This positions the company with a projected cash runway into the third quarter of 2025, indicating a solid financial footing for the near term.

https://finance.yahoo.com/news/cardiff-oncology-inc-crdf-reports-151216556.html

Adial Awarded New Patent

 Strengthens Adial’s patent portfolio and covers AD04’s unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorder

https://www.globenewswire.com/news-release/2024/02/28/2837060/26135/en/Adial-Pharmaceuticals-Awarded-New-Patent-from-the-United-States-Patent-and-Trademark-Office.html

BioVie: Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s

 Data from Phase 2a trial in Parkinson’s Disease suggest patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control while placebo-treated patients worsened

Data from Phase 3 trial in mild to moderate Alzheimer’s Disease suggest NE3107 may have the potential to realign physiological processes in patients consistent with decreased neurocognitive decline and diseases of aging

The presentation Improvement of Non-Motor Symptoms with NE3107 Adjunctive to Carbidopa/Levodopa in Patients with Parkinson’s Disease: A Phase 2A, Placebo-Controlled Study will be presented at 15:10 GMT on March 9, 2024 

https://www.globenewswire.com/news-release/2024/03/01/2838786/0/en/BioVie-s-NE3107-Demonstrates-Potential-Improvements-in-Motor-and-Non-motor-Symptoms-for-Parkinson-s-Disease-Patients-and-May-Be-Realigning-Physiological-Processes-for-Alzheimer-s-P.html

Missouri accuses Planned Parenthood of 'trafficking' minors to get abortions

 Missouri's Republican attorney general on Thursday sued a Planned Parenthood affiliate, accusing it of helping minors travel to Kansas to get abortions without notifying their parents in violation of state law.

The lawsuit by Attorney General Andrew Bailey cites undercover footage released by the conservative Project Veritas last year purporting to show a Planned Parenthood Great Plains employee offer to arrange an abortion for a 13-year-old in Kansas. Missouri law bans nearly all abortions, as well as helping a minor get an abortion out of state without parental consent.

Bailey's office called the lawsuit "the culmination of a multi-year campaign to drive Planned Parenthood from the State of Missouri," accusing it of violating other state laws in the past.

The attorney general is seeking an order from the Circuit Court of Boone County barring the reproductive health organization from helping minors get abortions.

A spokesperson for Planned Parenthood Great Plains said it does not provide transportation directly to patients. Its president, Emily Wales, said in a statement that the lawsuit was "based on 'evidence' from fraudulent, extreme anti-abortion actors" and that the organization would "continue following state and federal laws."

Project Veritas did not immediately respond to a request for comment.

Project Veritas frequently releases hidden camera footage seeking to show alleged wrongdoing by left-leaning organizations. It has frequently been accused of using deceptive tactics.

Missouri is one of about 20 Republican-led states that have banned or restricted abortion since the U.S. Supreme Court in 2022 overturned its 1973 Roe v. Wade ruling, which had guaranteed abortion rights nationwide.

Abortion remains legal until about 22 weeks in Kansas after voters in August 2022 rejected an effort to remove protections for it from the state's constitution.

https://finance.yahoo.com/news/missouri-accuses-planned-parenthood-trafficking-174106884.html